Clinics in Dermatology
Volume 25, Issue 6 , Pages 504-509 , November 2007

Three decades of psoriasis research: where has it led us?

  • Robert Sabat, MD

      Affiliations

    • Interdisciplinary Group of Molecular Immunopathology, Dermatology/Medical Immunology, University Hospital Charité, D-10117 Berlin, Germany
    • Corresponding Author InformationCorresponding author.
    • ,
  • Wolfram Sterry, MD, PhD

      Affiliations

    • Department of Dermatology and Allergy, University Hospital Charité, Berlin, D-10117 Germany
    • ,
  • Sandra Philipp

      Affiliations

    • Interdisciplinary Group of Molecular Immunopathology, Dermatology/Medical Immunology, University Hospital Charité, D-10117 Berlin, Germany
    • ,
  • Kerstin Wolk, MD

      Affiliations

    • Interdisciplinary Group of Molecular Immunopathology, Dermatology/Medical Immunology, University Hospital Charité, D-10117 Berlin, Germany

References 

  1. Voorhees JJ. Pathophysiology of psoriasis. Annu Rev Med. 1977;28:467–473
  2. Weinstein GD, Frost P. Abnormal cell proliferation in psoriasis. J Invest Dermatol. 1968;50:254–259
  3. Voorhees JJ. Regulation of epidermal proliferation and differentiation in psoriasis. J Dermatol. 1978;5:241–255
  4. Candi E, Schmidt R, Melino G. The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol. 2005;6:328–340
  5. Fuchs E. Epidermal differentiation: the bare essentials. J Cell Biol. 1990;111:2807–2814
  6. Allen M, Ishida-Yamamoto A, McGrath J, et al. Corneodesmosin expression in psoriasis vulgaris differs from normal skin and other inflammatory skin disorders. Lab Invest. 2001;81:969–976
  7. Flaxman BA, Harper RA. In vitro analysis of the control of keratinocyte proliferation in human epidermis by physiologic and pharmacologic agents. J Invest Dermatol. 1975;65:52–59
  8. Delecluse C, Fukuyama K, Epstein WL. Dibutyryl cyclic AMP-induced differentiation of epidermal cells in tissue culture. J Invest Dermatol. 1976;66:8–13
  9. Aso K, Orenberg EK, Farber EM. Reduced epidermal cyclic AMP accumulation following prostaglandin stimulation: its possible role in the pathophysiology of psoriasis. J Invest Dermatol. 1975;65:375–378
  10. Yoshikawa K, Adachi K, Halprin KM, Levine V. Is the cyclic AMP in psoriatic epidermis low?. Br J Dermatol. 1975;93:253–258
  11. Hammarstrom S, Hamberg M, Samuelsson B, Duell EA, Stawiski M, Voorhees JJ. Increased concentrations of nonesterified arachidonic acid, 12l-hydroxy-5,8,10,14-eicosatetraenoic acid, prostaglandin E2, and prostaglandin F2alpha in epidermis of psoriasis. Proc Natl Acad Sci U S A. 1975;72:5130–5134
  12. Jablonska S, Beutner EH, Binder WL, Jarzabek-Chorzelska M, Rzesa G, Chowaniec O. Immunopathology of psoriasis. Arch Dermatol Res. 1979;264:65–71
  13. van de Kerkhof PC, Chang A. Migration of polymorphonuclear leukocytes in psoriasis. Skin Pharmacol. 1989;2:138–154
  14. Schröder JM, Christophers E. Identification of C5ades arg and an anionic neutrophil-activating peptide (ANAP) in psoriatic scales. J Invest Dermatol. 1986;87:53–58
  15. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med. 1979;301:555
  16. Halloran PF, Kung L, Noujaim J. Calcineurin and the biological effect of cyclosporine and tacrolimus. Transplant Proc. 1998;30:2167–2170
  17. Cockerill GW, Bert AG, Ryan GR, Gamble JR, Vadas MA, Cockerill PN. Regulation of granulocyte-macrophage colony-stimulating factor and E-selectin expression in endothelial cells by cyclosporin A and the T-cell transcription factor NFAT. Blood. 1995;86:2689–2698
  18. Teunissen MB, De Jager MH, Kapsenberg ML, Bos JD. Inhibitory effect of cyclosporin A on antigen and alloantigen presenting capacity of human epidermal Langerhans cells. Br J Dermatol. 1991;125:309–316
  19. Al-Daraji WI, Grant KR, Ryan K, Saxton A, Reynolds NJ. Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A. J Invest Dermatol. 2002;118:779–788
  20. Nicolas JF, Chamchick N, Thivolet J, Wijdenes J, Morel P, Revillard JP. CD4 antibody treatment of severe psoriasis. Lancet. 1991;338:321
  21. Prinz J, Braun-Falco O, Meurer M, et al. Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet. 1991;338:320–321
  22. Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995;1:442–447
  23. Eedy DJ, Burrows D, Bridges JM, Jones FG. Clearance of severe psoriasis after allogenic bone marrow transplantation. BMJ. 1990;300:908
  24. Gardembas-Pain M, Ifrah N, Foussard C, et al. Psoriasis after allogeneic bone marrow transplantation. Arch Dermatol. 1990;126:1523
  25. Boehncke WH, Kaufmann R. Human to mouse xenotransplantation models complement transgenic and know-out mice. Comment on the contribution by K. Sellheyser: transgenic mice as models for skin diseases. Hautarzt. 1996;47:475–476
  26. Nickoloff BJ, Kunkel SL, Burdick M, Strieter RM. Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model. Am J Pathol. 1995;146:580–588
  27. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest. 1996;98:1878–1887
  28. Christophers E. The immunopathology of psoriasis. Int Arch Allergy Immunol. 1996;110:199–206
  29. Gottlieb AB. Immunologic mechanisms in psoriasis. J Am Acad Dermatol. 1988;18:1376–1380
  30. Prinz JC. Which T cells cause psoriasis?. Clin Exp Dermatol. 1999;24:291–295
  31. Valdimarsson H, Baker BS, Jonsdottir I, Powles A, Fry L. Psoriasis: a T-cell–mediated autoimmune disease induced by streptococcal superantigens?. Immunol Today. 1995;16:145–149
  32. Barker JN. Psoriasis as a T cell–mediated autoimmune disease. Hosp Med. 1998;59:530–533
  33. Bos JD, de Rie MA, Teunissen MB, Piskin G. Psoriasis: dysregulation of innate immunity. Br J Dermatol. 2005;152:1098–1107
  34. Philipp S, Wolk K, Kreutzer S, et al. The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder. Expert Opin Ther Targets. 2006;10:817–831
  35. Terajima S, Higaki M, Igarashi Y, Nogita T, Kawashima M. An important role of tumor necrosis factor-alpha in the induction of adhesion molecules in psoriasis. Arch Dermatol Res. 1998;290:246–252
  36. Teraki Y, Miyake A, Takebayashi R, Shiohara T. Homing receptor and chemokine receptor on intraepidermal T cells in psoriasis vulgaris. Clin Exp Dermatol. 2004;29:658–663
  37. Ding Z, Xiong K, Issekutz TB. Chemokines stimulate human T lymphocyte transendothelial migration to utilize VLA-4 in addition to LFA-1. J Leukoc Biol. 2001;69:458–466
  38. Bos JD, Hagenaars C, Das PK, Krieg SR, Voorn WJ, Kapsenberg ML. Predominance of “memory” T cells (CD4+, CDw29+) over “naive” T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch Dermatol Res. 1989;281:24–30
  39. Bovenschen HJ, Seyger MM, Van de Kerkhof PC. Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiation. Br J Dermatol. 2005;153:72–78
  40. Shamri R, Grabovsky V, Gauguet JM, et al. Lymphocyte arrest requires instantaneous induction of an extended LFA-1 conformation mediated by endothelium-bound chemokines. Nat Immun. 2005;6:497–506
  41. Baekkevold ES, Wurbel MA, Kivisakk P, et al. A role for CCR4 in development of mature circulating cutaneous T helper memory cell populations. J Exp Med. 2005;201:1045–1051
  42. Campbell JJ, Haraldsen G, Pan J, et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature. 1999;400:776–780
  43. Reiss Y, Proudfoot AE, Power CA, Campbell JJ, Butcher EC. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med. 2001;194:1541–1547
  44. Soler D, Humphreys TL, Spinola SM, Campbell JJ. CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking. Blood. 2003;101:1677–1682
  45. Rottman JB, Smith TL, Ganley KG, Kikuchi T, Krueger JG. Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest. 2001;81:335–347
  46. Nickoloff BJ, Karabin GD, Barker JN, et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol. 1991;138:129–140
  47. Stratis A, Pasparakis M, Rupec RA, et al. Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J Clin Invest. 2006;116:2094–2104
  48. Wang H, Peters T, Kess D, et al. Activated macrophages are essential in a murine model for T cell–mediated chronic psoriasiform skin inflammation. J Clin Invest. 2006;116:2105–2114
  49. Lowes MA, Chamian F, Abello MV, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A. 2005;102:19057–19062
  50. Ragaz A, Ackerman AB. Evolution, maturation, and regression of lesions of psoriasis. New observations and correlation of clinical and histologic findings. Am J Dermatopathol. 1979;1:199–214
  51. Wollenberg A, Wagner M, Gunther S, et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol. 2002;119:1096–1102
  52. Dumoutier L, Louahed J, Renauld JC. Cloning and characterization of IL-10–related T cell–derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol. 2000;164:1814–1819
  53. Wolk K, Sabat R. Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev. 2006;17:367–380
  54. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases the innate immunity of tissues. Immunity. 2004;21:241–254
  55. Wolk K, Witte E, Reineke U, et al. Is there an interaction between interleukin-10 and interleukin-22?. Genes Immun. 2005;6:8–18
  56. Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006;36:1309–1323
  57. Wolk K, Kunz S, Asadullah K, Sabat R. Cutting edge: immune cells as sources and targets of the IL-10 family members?. J Immunol. 2002;168:5397–5402
  58. Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol. 2004;76:314–321
  59. Langer JA, Cutrone EC, Kotenko S. The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions. Cytokine Growth Factor Rev. 2004;15:33–48
  60. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol. 2004;22:929–979
  61. Blumberg H, Conklin D, Xu WF, et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell. 2001;104:9–19
  62. Volk H, Asadullah K, Gallagher G, Sabat R, Grutz G. IL-10 and its homologs: important immune mediators and emerging immunotherapeutic targets. Trends Immunol. 2001;22:414–417
  63. Kunz S, Wolk K, Witte E, et al. Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol. 2006;15:991–1004
  64. Sabat R, Wallace E, Endesfelder S, Wolk K. IL-19 and IL-20: two novel cytokines with importance in inflammatory diseases. Expert Opin Ther Targets. 2007;11:601–612
  65. Kingo K, Koks S, Nikopensius T, Silm H, Vasar E. Polymorphisms in the interleukin-20 gene: relationships to plaque-type psoriasis. Genes Immun. 2004;5:117–121
  66. Koks S, Kingo K, Ratsep R, Karelson M, Silm H, Vasar E. Combined haplotype analysis of the interleukin-19 and -20 genes: relationship to plaque-type psoriasis. Genes Immun. 2004;5:662–667
  67. Koks S, Kingo K, Vabrit K, et al. Possible relations between the polymorphisms of the cytokines IL-19, IL-20 and IL-24 and plaque-type psoriasis. Genes Immun. 2005;6:407–415
  68. Otkjaer K, Kragballe K, Funding AT, et al. The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis. Br J Dermatol. 2005;153:911–918
  69. Romer J, Hasselager E, Norby PL, Steiniche T, Thorn J, Clausen K. Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol. J Invest Dermatol. 2003;121:1306–1311
  70. Wei CC, Chen WY, Wang YC, et al. Detection of IL-20 and its receptors on psoriatic skin. Clin Immunol. 2005;117:65–72
  71. Liu L, Ding C, Zeng W, et al. Selective enhancement of multipotential hematopoietic progenitors in vitro and in vivo by IL-20. Blood. 2003;102:3206–3209
  72. Sano S, Chan KS, Carbajal S, et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med. 2005;11:43–49
  73. Sano S, Itami S, Takeda K, et al. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. Embo J. 1999;18:4657–4668
  74. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715–725
  75. Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit. IL-23R. J Immunol. 2002;168:5699–5708
  76. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203:2577–2687
  77. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199:125–130
  78. Sabat R, Philipp S, Höflich C, et al. Immunopathogenesis of psoriasis. Exp Derm. 2007;16:779–798

PII: S0738-081X(07)00146-0

doi: 10.1016/j.clindermatol.2007.08.002

Clinics in Dermatology
Volume 25, Issue 6 , Pages 504-509 , November 2007

Article Tools